Leading pharmaceutical company trusts Calyx to meet accelerated timelines and support multi-year trials
Nottingham, England and Morrisville, NC – February 21, 2022 – Calyx, the eClinical and Regulatory solutions and services provider relied on for solving complex data challenges in clinical research, today announced its electronic data capture (EDC) system has been selected by a leading pharmaceutical company to capture Real World Evidence (RWE) data for a global, late phase study.
The global company selected Calyx EDC based on its proven effectiveness in capturing important clinical trial patient data during lengthy, global studies. Calyx’s ability to expedite the delivery of a reliable, cost-effective solution to meet the pharmaceutical company’s accelerated study timelines and continuous data collection needs were critical to its selection.
“We’re thrilled to work with this leading pharmaceutical company and to extend our 30 years’ experience in delivering reliable, high-quality data to help them fully understand the long-term effects of their medical products.” said Juan Munoz-Pujol, Vice President, IRT and EDC at Calyx.
Click here for more information on Calyx EDC.
Through innovative eClinical and Regulatory solutions and services, Calyx turns the uncertain into the reliable, helping bring new medical treatments to market reliably. With deep expertise in clinical development and 30 years supporting trial sponsors and clinical research organizations, Calyx harnesses its intelligence and experience to solve complex problems, deliver fast insights, and get new drugs to market every day.
Christine Tobin | Christine.Tobin@Calyx.ai | +1 412-628-8598